Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CARsgen Therapeutics Holdings's quarterly market cap
increased
from Dec. 2024 (HK$5,076.5 Mil) to Jun. 2025 (HK$12,791.1 Mil) but then
declined
from Jun. 2025 (HK$12,791.1 Mil) to Dec. 2025 (HK$8,023.1 Mil).
CARsgen Therapeutics Holdings's annual market cap
increased
from Dec. 2023 (HK$3,622.0 Mil) to Dec. 2024 (HK$5,076.5 Mil) and
increased
from Dec. 2024 (HK$5,076.5 Mil) to Dec. 2025 (HK$8,023.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CARsgen Therapeutics Holdings's Enterprise Value for Today is HK$7,150.5 Mil.
CARsgen Therapeutics Holdings (HKSE:02171) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CARsgen Therapeutics Holdings Market Cap Related Terms
CARsgen Therapeutics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02171 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARsgen Therapeutics Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where CARsgen Therapeutics Holdings's Market Cap falls into.
CARsgen Therapeutics Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings (HKSE:02171) has a Market Cap of HK$8,490.5 Mil as of Aug. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CARsgen Therapeutics Holdings and its competitors. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #279 out of 1422 companies in the Biotechnology industry, placing it in the top 19.6%.
Is CARsgen Therapeutics Holdings' Market Cap too high?
CARsgen Therapeutics Holdings' current Market Cap is HK$8,490.5 Mil. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #279 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #279 out of 1422 companies for Market Cap. This places CARsgen Therapeutics Holdings in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.56, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CARsgen Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 117.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARsgen Therapeutics Holdings's current Market Cap is HK$8,490.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (HKSE:02171) has a current Market Cap of HK$8,490.5 Mil. The current Market Cap is HK$8,490.5 Mil. CARsgen Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (HKSE:02171), the current Market Cap is HK$8,490.5 Mil as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
32GF Score
Get the complete analysis for HKSE:02171
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02171 has been successfully added to your 
